Bildkälla: Stockfoto

Idogen: Funding in Focus - Redeye

Redeye comments on Idogen following its report for the third quarter of 2022. We also comment on the announced rights issue and the financial position of Idogen.

Redeye comments on Idogen following its report for the third quarter of 2022. We also comment on the announced rights issue and the financial position of Idogen.
Börsvärldens nyhetsbrev
ANNONSER